2-(苄氧基)-4-溴苯甲醚 | 78504-28-6

• 物质功能分类: 有机原料 - 醚类化合物及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(苄氧基)-4-溴苯甲醚
• 英文名称: 2-Benzyloxy-4-bromo-1-methoxybenzene
• 英文别名: 2-benzyl oxy-4-bromoanisole；2-(Benzyloxy)-4-bromo-1-methoxybenzene；4-bromo-1-methoxy-2-phenylmethoxybenzene
• CAS: 78504-28-6
• 化学式: C₁₄H₁₃BrO₂
• 分子量: 293.16
• InChiKey: OFFXGGNLPNBCBO-UHFFFAOYSA-N

物化性质

• 熔点：
  45-46 °C
• 沸点：
  358.9±27.0 °C(Predicted)
• 密度：
  1.367±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应储存在室温下，保持密封和干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Benzyloxy)-4-bromoanisole
Synonyms: 2-(Benzyloxy)-4-bromo-1-methoxybenzene

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Benzyloxy)-4-bromoanisole
CAS number: 78504-28-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H13BrO2
Molecular weight: 293.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(苄氧基)-4-溴苯甲醚 在 吡啶 、 (R)-(+)-5,5'-双[二(3,5-二甲苯基)膦]-4,4'-二-1,3-苯并二茂 、 盐酸 、 甲醇 、 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 正丁基锂 、 双[Α,Α-双(三氟甲基)苯甲醇合]二苯硫 、 bis(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate 、 10 wt% Pd(OH)2 on carbon 、 水 、 氢气 、 silica gel 、 三溴化硼 、 potassium carbonate 、 caesium carbonate 、 对甲苯磺酸 、 溶剂黄146 、 三苯基膦 、 sodium naphthalenide 、 pyridinium chlorochromate 、 偶氮二甲酸二乙酯 、 乙硫醇钠 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 苯 为溶剂， 反应 305.67h， 生成 4-羟基-3-甲氧基-17-甲基吗喃-6-酮
  参考文献：
  名称：

  吗啡族生物碱(−)-蒂巴酮A的解构不对称全合成

  摘要：

  在此，我们描述了首次不对称合成 (−)-蒂巴因酮 A 的解构策略的开发，利用对映选择性 C−C 键激活和 C−O 键裂解反应。铑催化的空间位阻三取代烯烃和苯并环丁烯酮之间的不对称“剪切和缝合”转化允许有效构建稠合的A/B/C环和天然产物的四元中心。新优化的条件显示出广泛的底物范围和出色的对映选择性（高达 99.5:0.5 er）。利用硼介导的醚键断裂，我们通过两条互补路线完成了吗啡生物碱(−)-蒂巴因酮A的合成。

  DOI：

  10.1002/anie.202103553
• 作为产物：
  描述：

  木榴油 在 4-二甲氨基吡啶 、 N-溴代丁二酰亚胺(NBS) 、 potassium carbonate 、 三乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 丙酮 、 乙腈 为溶剂， 反应 29.08h， 生成 2-(苄氧基)-4-溴苯甲醚
  参考文献：
  名称：

  异槲皮酚的合成及其抗炎活性。

  摘要：

  我们在这里报告了异方苯酚的合成，异方苯酚是枫糖浆中发现的多酚化合物quebecol的前所未有的结构异构体。制备异白酚的方法学涉及关键步骤，即由α-酮酸酯前体形成二溴代烯烃，然后进行Suzuki-Miyaura双反应。通过监测其抑制LPS诱导的IL-6分泌的能力，研究了异黄柏对巨噬细胞的抗炎活性。结果表明，这种新化合物具有比其天然异构体更高的生物活性。这项研究中还制备了quebecol，异quebecol和模型类似物2,3,3-三苯丙醇的前体和衍生物。

  DOI：

  10.1016/j.bmc.2017.01.050

文献信息

• Substituted dibenzo[ c,h ]cinnolines: topoisomerase I-targeting anticancer agents
  作者：Younong Yu、Sudhir K Singh、Angela Liu、Tsai-Kun Li、Leroy F Liu、Edmond J LaVoie

  DOI：10.1016/s0968-0896(02)00604-1

  日期：2003.4

  9-methylenedioxybenzo[i]phenanthridine is one of the more potent benzo[i]phenanthridine derivatives in regard to topoisomerase I-targeting activity and cytotoxicity. The structure-activity relationship observed with these substituted dibenzo[c,h]cinnolines parallels that observed for benzo[i]phenanthridine derivatives. Compared to similarly substituted benzo[i]phenanthridines, the dibenzo[c,h]cinnoline analogues

  合成了几种取代的二苯并[c，h]肉桂啉，并评估了其靶向拓扑异构酶I的潜力以及相对的细胞毒性活性。选择的苯并[i]菲啶能够稳定由拓扑异构酶I和DNA形成的可裂解复合物。开始这项研究以检查本质上是苯并[i]菲啶的氮杂类似物的二苯并[c，h] cinnolines是否具有相似的药理特性。就靶向拓扑异构酶I的活性和细胞毒性而言，2，3-二甲氧基-8，9-亚甲基二氧基苯并[i]菲啶是更有效的苯并[i]菲啶衍生物之一。用这些取代的二苯并[c，h] cinnolines观察到的结构活性关系与苯并[i]菲啶衍生物观察到的相似。与类似取代的苯并[i]菲啶相比，二苯并[c，h] cinnoline类似物表现出更强的拓扑异构酶I靶向活性和细胞毒性。在评估2,3-二甲氧基-8,9-亚甲基二氧基二苯并[c，h] cinnoline和2,3-二甲氧基-8,9-亚甲基二氧基苯并[i]菲啶在人淋巴母细胞瘤中的细胞毒性时获
• [EN] FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS TRYCICLIQUES CONDENSÉS ET UTILISATIONS CORRESPONDANTES EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2018219356A1

  公开（公告）日：2018-12-06

  The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The invention also relates to the use of the compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

  本发明涉及一种融合三环化合物及其作为药物的用途，特别是作为治疗和/或预防乙型肝炎的药物。具体地，本发明涉及具有化学式（I）或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药学上可接受的盐或其前药的化合物，其中每个变量如规范中所定义。本发明还涉及将具有化学式（I）或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药学上可接受的盐或其前药用作药物，特别是作为治疗和/或预防乙型肝炎的药物。
• [EN] NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVEAUX DÉRIVÉS DE 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016071215A1

  公开（公告）日：2016-05-12

  The invention provides novel compounds having the general formula (I) wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般式（I）的新化合物，其中R1至R6、W和X如本文所述，以及它们的药用盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation
  作者：Nicky Hwang、Liren Sun、Daisy Noe、Patrick Y. S. Lam、Tianlun Zhou、Timothy M. Block、Yanming Du

  DOI：10.1021/acsmedchemlett.1c00228

  日期：2021.7.8

  with a dihydroquinolizinone (DHQ) scaffold has been shown to reduce circulating levels of HBsAg in animals, representing a first for a small molecule. Reductions of HBsAg were a result of the compound’s effect on HBsAg mRNA levels. However, commercial development by Roche of a DHQ lead compound, RG-7834, was stopped due to undisclosed toxicity issues. Herein we report our effort to convert the systemic

  慢性乙型肝炎 (CHB) 的特征是血液循环中的乙型肝炎病毒 (HBV) 表面抗原 (HBsAg) 水平较高。CHB 干预的一个主要目标是减少或消除这种抗原血症。但是，目前没有批准的方法可以做到这一点。具有二氢喹啉酮 (DHQ) 支架的新型化合物家族已被证明可以降低动物体内 HBsAg 的循环水平，这是小分子的首创。HBsAg 的降低是化合物对 HBsAg mRNA 水平的影响的结果。然而，由于未公开的毒性问题，罗氏停止了 DHQ 先导化合物 RG-7834 的商业开发。在这里，我们报告了我们将全身性 RG7834 化合物转化为肝选择性 DHQ 类似物以限制其分布到血液中并因此限制到其他身体组织的努力。
• Benzopyran derivatives and pharmaceutical compositions containing them
  申请人：Rhone-Poulenc Sante

  公开号：US04977166A1

  公开（公告）日：1990-12-11

  New benzopyran derivatives of formula: ##STR1## in which R.sub.1 is hydrogen, halogen, hydroxy, alkoxy, nitro, amino, alkylsulphonamido, bis(alkylsulphonyl) amino or acylamino, X is nitrogen or a >CH-radical R is a radical of formula: ##STR2## in which A denotes a single bond or methylene or, when X is nitrogen, A may denote carbonyl, and R.sub.2 and R.sub.3, which are identical or different, are hydrogen, halogen, hydroxy, alkyl, alkoxy, nitro, amino, alkylsulphonamido, bis(alkylsulphonyl)amino, acylamino, sulphamoyl or cyano, or, when they are adjacent, together form a methylenedioxy or ethylenedioxy radical, or else R is pyridyl or 2(2H)-benzimidazolonyl if X denotes >CH--, and R' and R" are identical and are hydrogen or alkyl, their isomeric forms and mixtures thereof, and their acid addition salts, can be used as antiarrhythmic and antifibrillation agents.

  新的苯并吡喃衍生物的化学式为：##STR1## 其中 R.sub.1 是氢、卤素、羟基、烷氧基、硝基、氨基、烷基磺酰胺基、双(烷基磺酰基)氨基或酰胺基，X 是氮或一个 >CH-基团，R 是一个化学式的基团：##STR2## 其中 A 表示一个单键或亚甲基，或者当 X 是氮时，A 可表示羰基，R.sub.2 和 R.sub.3，它们相同或不同，是氢、卤素、羟基、烷基、烷氧基、硝基、氨基、烷基磺酰胺基、双(烷基磺酰基)氨基、酰胺基、磺酰胺基或氰基，或者当它们相邻时，一起形成一个亚甲二氧基或乙烯二氧基基团，或者 R 是吡啶基或 2(2H)-苯并咪唑基，如果 X 表示 >CH--，而 R' 和 R" 相同且是氢或烷基，它们的异构体形式和混合物，以及它们的酸盐加合物，可用作抗心律失常和抗纤颤剂。